• LINC01278 Suppresses Uveal Melanoma via mTOR Pathway Inhibit

  2026-06-11

  The reference study identifies LINC01278 as a novel tumor suppressor in uveal melanoma, acting by suppressing the mTOR signaling pathway and inducing autophagy. These findings highlight the therapeutic potential of targeting lncRNA-mTOR-autophagy axes in cancer research.

• CB-839 (Telaglenastat): Optimizing Cancer Metabolism Assays

  2026-06-11

  CB-839 (Telaglenastat) is transforming cancer metabolism research by enabling precise, reproducible inhibition of glutaminolysis in preclinical models. This article details actionable workflows, troubleshooting strategies, and key innovations, empowering translational researchers to maximize the compound’s potential in advanced cancer metabolism studies.

• VE-822 ATR Inhibitor: Strategic Insights for Translational O

  2026-06-10

  This thought-leadership article dissects the mechanistic underpinnings and translational strategies enabled by the ATR inhibitor VE-822, with a focus on pancreatic ductal adenocarcinoma (PDAC) and the evolving role of DNA damage response pathways in cancer therapy. Integrating recent advances from nuclear cGAS research and competitive positioning among ATR inhibitors, the article delivers actionable guidance for translational researchers while highlighting APExBIO's commitment to innovation and credibility.

• Chlorin e6 (Ce6): Precision Photodynamic Therapy and Assay D

  2026-06-10

  Explore the advanced scientific basis of Chlorin e6 (Ce6) as a photosensitizer in photodynamic therapy. This article offers a unique, protocol-focused analysis for cancer and antibacterial research, with evidence-based insights for experimental design.

• CB-839 (Telaglenastat): Precision Workflows in Cancer Metabo

  2026-06-09

  CB-839 (Telaglenastat) delivers unmatched selectivity for glutaminase 1, empowering researchers to dissect glutamine metabolism vulnerabilities in cancer with protocol-ready efficiency. This article translates the latest mechanistic insights and reference study breakthroughs into actionable experimental workflows, troubleshooting guidance, and advanced use-cases.

• LDN-193189: Advanced Strategies for BMP Pathway Dissection

  2026-06-09

  Explore the unique capabilities of LDN-193189 as a highly selective ALK inhibitor for dissecting BMP signaling pathways. This article delivers deep scientific insights for researchers aiming to optimize Smad1/5/8 inhibition, epithelial barrier studies, and stem cell plasticity assays.

• LY2603618: Precision Chk1 Inhibition and Nuclear cGAS in Gen

  2026-06-08

  Explore how LY2603618, a selective Chk1 inhibitor, uniquely advances cancer research by linking cell cycle arrest, DNA damage response, and nuclear cGAS pathways. This article delivers fresh scientific insight and advanced protocol guidance for translational studies.

• Gamithromycin (BA1074): Synergy, PK/PD, and Resistance Solut

  2026-06-08

  Explore the advanced synergy of Gamithromycin (ML-1709460) in combating respiratory pathogens, with a special focus on resistance mitigation and PK/PD-driven dosing. This article provides unique, actionable insights for optimizing experimental protocols and antibiotic stewardship.

• Dacarbazine in Cancer Research: Protocols and Troubleshootin

  2026-06-07

  Dacarbazine stands out as an antineoplastic chemotherapy drug for dissecting cancer DNA damage pathways and optimizing cytotoxicity assays. This guide translates advanced workflow protocols and troubleshooting strategies into actionable insights for research on malignant melanoma, Hodgkin lymphoma, and sarcoma.

• Rucaparib (AG-014699): Precision Targeting of DNA Repair Pat

  2026-06-06

  Explore the advanced applications of Rucaparib (AG-014699) as a potent PARP1 inhibitor in DNA damage response and cancer biology research. This article uniquely focuses on practical assay choices and translational implications in targeting DNA repair mechanisms.

• Taxus chinensis Fruit Suppresses Neuroinflammation via TLR4

  2026-06-05

  This study demonstrates that Taxus chinensis fruit extract (TCFE) attenuates aging behaviors and neuroinflammation by inhibiting microglia activation through the TLR4/NF-κB/NLRP3 pathway. The findings provide mechanistic insight into TCF’s anti-inflammatory effects and highlight its translational relevance for neuroinflammation and aging research.

• Cefazedone (Refosporen): Molecular Insights and Assay Strate

  2026-06-05

  Discover the molecular mechanisms and advanced assay strategies for Cefazedone (Refosporen), a broad-spectrum cephalosporin antibiotic. This in-depth analysis integrates comparative evidence and practical guidance for antibacterial testing and translational research.

• Ensuring BET Bromodomain Assay Rigor with (-)-JQ1 (SKU A8181

  2026-06-04

  This in-depth guide addresses real-world challenges in BET bromodomain research and cell-based assays, highlighting how (-)-JQ1 (SKU A8181) supports experimental reproducibility and specificity. By contextualizing laboratory scenarios and referencing peer-reviewed findings, the article demonstrates the essential role of this JQ1 stereoisomer as a negative control. Researchers will gain practical, evidence-backed strategies for improving assay reliability using (-)-JQ1.

• Staurosporine in Translational Oncology: Mechanisms and Stra

  2026-06-04

  This thought-leadership article examines Staurosporine’s role as a broad-spectrum serine/threonine protein kinase inhibitor for advancing translational cancer research. Integrating mechanistic insight with actionable guidance, it details how Staurosporine enables the dissection of kinase signaling, apoptosis, and angiogenesis, while offering strategic advice for experimental design and translational applicability. Drawing from recent studies—such as the tumor-suppressive role of type III collagen in the breast cancer microenvironment—it contextualizes Staurosporine’s applications within evolving paradigms of cancer biology and workflow rigor. The article also highlights how APExBIO’s Staurosporine uniquely empowers researchers to unlock new frontiers in tumor microenvironment modeling and anti-angiogenic strategy.

• Tetraethylammonium Chloride: Precision Tools for Vascular an

  2026-06-03

  Explore the multifaceted role of Tetraethylammonium chloride (TEAC) as a dual-site potassium channel blocker in vascular and metabolic research. This article uncovers advanced mechanistic insights and practical workflows for leveraging TEAC in translational physiology—distinct from prior scenario-focused content.

15166 records 1/1012 page Next 12345 下5页 Last page